Betaxolol hydrochloride

CLINICAL USE

Hyperlipidaemia

DOSE IN NORMAL RENAL FUNCTION

200 mg, 3 times a day Modified release: 400 mg daily

PHARMACOKINETICS

Molecular weight :361.8

%Protein binding :95

%Excreted unchanged in urine : 50

Volume of distribution (L/kg) :0.24–0.35

half-life – normal/ESRD (hrs) :1–2 (XL: 3.4)/7.8–20

DOSE IN RENAL IMPAIRMENT

GFR (mL/MIN)

40–60 400 mg daily15–40 200 mg every 24–48 hours<15 Avoid

DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

CAPD :Not dialysed. 200 mg every 72 hours

HD :Not dialysed. 200 mg every 72 hours

HDF/high flux :Unknown dialysability. 200 mg every 72 hours

CAV/VVHD :Unknown dialysability. Dose as in GFR=15–40 mL/min

IMPORTANT DRUG INTERACTIONS

Potentially hazardous interactions with other drugsAntibacterials: increased risk of myopathy with daptomycin – try to avoid concomitant useAnticoagulants: enhances effect of coumarins and phenindione; dose of anticoagulant should be reduced by up to 50% and adjusted by monitoring INRAntidiabetics: may improve glucose tolerance and have an additive effect with insulin or sulphonylureasCiclosporin: may increase nephrotoxicity and reduce ciclosporin levelsLipid-regulating drugs: increased risk of myopathy in combination with statins and ezetimibe – avoid with ezetimibe; do not exceed 10 mg of simvastatin1

ADMINISTRATION

Reconstition

–

Route

Oral

Rate of Administration

–

Comments

–

OTHER INFORMATION

Take dose with or after food Contraindicated in nephrotic syndrome There should be an interval of 2 hours between intake of ion exchange resin and bezafibrateModified-release preparation is not appropriate in renal impairment

See how to identify renal failure stages according to GFR calculation

See how to diagnose irreversible renal disease

Home